CIK 0000879169 · Large accelerated filer
INCYTE CORP
Sign in to watch- Ticker
- INCY
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943136539
- Phone
- 3024986700
- Business address
- 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
- Former names
- INCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $32,959,897
- in 5 filings, $33.0M under 10b5-1 plans
Net −$32,959,897. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise 10b5-1 | +455 | $61.18 | $28K | 184,917 |
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise 10b5-1 | +925 | $64.25 | $59K | 185,842 |
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −2,642 | $112.71 | $298K | 183,200 |
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −839 | 17,627 | ||
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −423 | 3,802 | ||
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −455 | 4,096 | ||
| 2026-10-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −925 | 19,431 | ||
| 2026-10-01 | Heeson Lee EVP, Head of Incyte Intl | Shares withheld for taxes | −463 | $117.14 | $54K | 37,578 |
| 2026-09-30 | Clancy Paul J Director | Grant or award | +203 | $121.35 | $25K | 25,838 |
| 2026-09-30 | BAKER BROS. ADVISORS LP Director | Grant or award | +322 | 2,835,403 | ||
| 2026-09-30 | BAKER BROS. ADVISORS LP Director | Grant or award | +322 | 28,206,082 | ||
| 2026-09-30 | HARRIGAN EDMUND Director | Grant or award | +206 | $121.35 | $25K | 23,225 |
| 2026-09-22 | Gardner David H EVP, Chief Strategy Officer | Shares withheld for taxes | −920 | $126.93 | $117K | 15,904 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise 10b5-1 | +2,957 | $61.76 | $183K | 186,157 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise 10b5-1 | +4,551 | $61.18 | $278K | 190,708 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise 10b5-1 | +6,477 | $64.25 | $416K | 197,185 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise 10b5-1 | +9,233 | $71.93 | $664K | 206,418 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −9,233 | $120.50 | $1.1M | 197,185 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −13,985 | $120.49 | $1.7M | 183,200 |
| 2026-09-15 | CAGNONI PABLO J President, Global Head of R&D | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,957 | 4,225 |
Page 3 of 15 · 293 trades